The underlying growth of the life sciences sector—pharmaceutical, biotech, and medtech—is strong at a combined US$2.83T.1,2,3 While growth has recently remained strong through increased demand and throughout the pandemic response (particularly with COVID-19 vaccines), we are seeing life sciences companies shifting their portfolio strategies with the hope of continuing this growth trajectory by any combination of acquisitions, divestitures of assets deemed not core to growth; investments in R&D and an accelerated embracing of digital; and data technologies which are finally beginning to scale in their adoption. Significant challenges remain though, such as the increasingly competitive market, the changing and evolving regulatory landscape, increasing pricing and reimbursement pressures, and growing demands from patients and health care providers for more effective medications and experiences as they manage health and well-being. All of this also while in the face of broader geopolitical and economic uncertainty.

Overview & Outlook 

Evolving portfolios and value creation 

R&D 

Supply chain again a CEO agenda 

Pricing and reimbursement 

Patient centricity 

Digital transformation 

Elevating health equity 

Contacts 

Learn more

Endnotes